ストックスクリーナーアプリを入手
903.99
0.11%
-1.04
アフターアワーズ：
903.00
-0.99
-0.11%
前日終値:
$905.03
開ける：
$911.665
24時間の取引高:
2.83M
Relative Volume:
0.91
時価総額：
$807.59B
収益：
$65.18B
当期純損益:
$20.64B
株価収益率:
40.02
EPS:
22.5894
ネットキャッシュフロー:
$5.96B
1週間 パフォーマンス:
-5.36%
1か月 パフォーマンス:
-8.61%
6か月 パフォーマンス:
+10.33%
1年 パフォーマンス:
+23.01%
1日の値動き範囲:
$898.15
$920.00
1週間の範囲:
$888.03
$963.94
52週間の値動き範囲:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Compare LLY vs JNJ, ABBV, AZN, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
903.99 | 808.52B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
234.54 | 574.86B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
208.99 | 368.65B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
200.47 | 312.04B | 58.80B | 10.24B | 8.98B | 3.2788 |
NVS
Novartis Ag Adr
|
149.73 | 290.19B | 54.72B | 14.02B | 15.32B | 7.1855 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-17 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2026-02-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2026-02-20 | 開始されました | Barclays | Overweight |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-12-16 | アップグレード | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | 繰り返されました | BofA Securities | Buy |
| 2025-12-15 | 繰り返されました | Goldman | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-11-10 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | 繰り返されました | BMO Capital Markets | Outperform |
| 2025-10-14 | アップグレード | Erste Group | Hold → Buy |
| 2025-09-17 | ダウングレード | Berenberg | Buy → Hold |
| 2025-08-27 | アップグレード | HSBC Securities | Reduce → Hold |
| 2025-08-18 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | ダウングレード | Erste Group | Buy → Hold |
| 2025-04-28 | ダウングレード | HSBC Securities | Buy → Reduce |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-09-13 | 再開されました | Citigroup | Buy |
| 2024-08-12 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-02-21 | ダウングレード | DZ Bank | Buy → Hold |
| 2024-02-16 | 繰り返されました | Morgan Stanley | Overweight |
| 2023-12-21 | ダウングレード | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-10-20 | 再開されました | UBS | Buy |
| 2023-08-09 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-26 | 繰り返されました | Citigroup | Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-05-24 | 繰り返されました | BofA Securities | Buy |
| 2023-05-24 | 繰り返されました | UBS | Buy |
| 2023-03-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-02-15 | ダウングレード | Societe Generale | Hold → Sell |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-09-22 | アップグレード | UBS | Neutral → Buy |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2022-03-10 | 開始されました | Daiwa Securities | Outperform |
| 2022-01-21 | アップグレード | DZ Bank | Hold → Buy |
| 2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-16 | 繰り返されました | BMO Capital Markets | Outperform |
| 2021-12-16 | 繰り返されました | BofA Securities | Buy |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-10-11 | アップグレード | Berenberg | Hold → Buy |
| 2021-09-29 | アップグレード | Citigroup | Neutral → Buy |
| 2021-08-05 | アップグレード | DZ Bank | Hold → Buy |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-06-24 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2021-01-19 | アップグレード | Mizuho | Neutral → Buy |
| 2020-12-10 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-09-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-04-21 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2019-12-18 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-05-28 | 開始されました | Goldman | Buy |
| 2019-04-24 | アップグレード | Edward Jones | Hold → Buy |
| 2019-04-11 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-03-12 | 開始されました | JP Morgan | Overweight |
| 2019-01-23 | 開始されました | UBS | Buy |
| 2018-11-26 | ダウングレード | Citigroup | Buy → Neutral |
| 2018-10-31 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2018-10-01 | 繰り返されました | SunTrust | Buy |
| 2018-09-26 | 再開されました | JP Morgan | Overweight |
すべてを表示
Lilly Eli Co (LLY) 最新ニュース
Lilly Reports 57% Lower Death Risk in Foundayo Cardiovascular St - GuruFocus
Lilly’s Foundayo lowers heart attack, stroke risk in study - USA Today
Lilly Clears Cardiovascular Overhang on Foundayo - GuruFocus
ATUM Names Genentech and Eli Lilly Veteran Gavin Barnard as Chief Scientific Officer - citybiz
Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight - GlobeNewswire Inc.
Lilly eyes diabetes expansion for Foundayo after Phase III CV outcomes trial - FirstWord Pharma
US appeals court revives Teva lawsuit against Eli Lilly over migraine drug - Reuters
Braun administration, Eli Lilly to collaborate on nuclear power development - Indianapolis Business Journal
Leerink reiterates Eli Lilly stock rating on diabetes drug results - Investing.com
Is This $6.3 Billion Deal a Game Changer for Eli Lilly? - AOL.com
Eli Lilly (LLY) Stock Rises as Foundayo Obesity Pill Cuts Heart Death Risk by Over Half - CoinCentral
Gov. Mike Braun Signs Nuclear Energy Letter Of Intent With Eli Lilly And Company - InkFreeNews.com
Eli Lilly Releases Updated Safety Data for Foundayo Following FDA’s Request - Pharmaceutical Executive
Eli Lilly Expands TuneLab With Vasa AI Tie Up For Drug Discovery - simplywall.st
Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson - Benzinga
Lilly confirms date and conference call for first-quarter 2026 financial results announcement - marketscreener.com
Eli Lilly schedules April 30 webcast for first-quarter 2026 results - Stock Titan
Govenor Mike Braun signs Nuclear Energy Letter of Intent with Eli Lilly and Company - WBIW
Lilly answers FDA's call for more Foundayo safety info, plotting diabetes filing in parallel - Fierce Pharma
Lilly says Foundayo pill lowers heart attack, stroke risk in study - Reuters
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Immunocore Holdings (IMCR) - The Globe and Mail
What Is Foundayo? Eli Lilly's New Diabetes Drug Is Drawing Fresh Retail Attention - Stocktwits
Governor Braun, Eli Lilly sign letter of intent to explore nuclear energy in Indiana - wevv.com
Lilly obesity pill shows no added heart risk in trial - MSN
Eli Lilly's New Oral Weight Loss Drug Clears Cardiovascular Bar - Benzinga
Eli Lilly (LLY) Announces Positive Phase 3 Results for Foundayo in Type 2 Diabetes - GuruFocus
Eli Lilly Reveals Results of Late-Stage Study for Type 2 Diabetes Treatment - WSJ
Lilly’s new obesity pill passes heart safety test in diabetes - Yahoo
Lilly to seek FDA nod for obesity pill in diabetes (LLY:NYSE) - Seeking Alpha
Eli Lilly reports Foundayo met primary objective in Phase 3 ACHIEVE-4 study - TipRanks
Lobbying Update: $120,000 of ELI LILLY AND COMPANY lobbying was just disclosed - Quiver Quantitative
Lilly’s Foundayo meets cardiovascular safety goal in diabetes trial By Investing.com - Investing.com Canada
Lilly’s Foundayo Obesity Pill Matches Insulin in Heart Study - Bloomberg.com
Daily diabetes pill beats insulin on weight, A1C and heart safety - Stock Titan
Hedeker Wealth LLC Has $9.73 Million Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Hardman Johnston Global Advisors LLC Acquires 20,752 Shares of Eli Lilly and Company $LLY - MarketBeat
Market Street Wealth Management Advisors LLC Has $18.14 Million Stock Position in Eli Lilly and Company $LLY - MarketBeat
Sumitomo Mitsui Trust Group Inc. Sells 102,900 Shares of Eli Lilly and Company $LLY - MarketBeat
Prediction: This 1 Thing Could Cement Eli Lilly's Leadership in the Billion-Dollar Weight Loss Drug Market - The Motley Fool
Greenup Street Wealth Management LLC Takes Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Sold by Altfest L J & Co. Inc. - MarketBeat
Gov. Mike Braun signs nuclear energy letter with Eli Lilly - nwitimes.com
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
FDA asks drugmaker Eli Lilly for more safety information on its new GLP-1 weight loss pill - AOL.com
FDA asks Eli Lilly for more safety info on its new GLP-1 weight loss pill - The Independent
The $1 Trillion Race: Why Eli Lilly Is Leaving Novo Nordisk in the Dust - The Motley Fool
Eli Lilly Navigates Regulatory and Pipeline Milestones Ahead of Earnings - AD HOC NEWS
Selling pressure pushes Eli Lilly stock lower in today's trading - Traders Union
Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to Tumors - MedCity News
BMO reiterates Eli Lilly stock Outperform on manageable post-marketing requirements - Investing.com Australia
Lilly to acquire CrossBridge Bio for up to $300m - Pharmaceutical Technology
Lilly Eli Co (LLY) 財務データ
収益
当期純利益
現金流量
EPS
1.73%
0.27%
大文字化:
|
ボリューム (24 時間):